Important Information
Please note, we need you to ….
- Read the important documents for this study
- If you are interested, look at the dates that this study is being run (cohort visit planners) and reply to our email (don’t re-register online) to let us know which cohort(s) you are available for
- We will ring you to check your suitability and provide further information about the study
- We will make you a screening appointment at NZCR Christchurch. You will need to attend at the scheduled time if you wish to take part in the study
Study Information
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has driven the Coronavirus Disease 2019 (COVID-19) pandemic since 2020. Throughout the course of the pandemic, global efforts have been made to provide protection and control measures to reduce the spread of COVID-19.
Moderna and the National Institute of Allergy and Infectious Diseases have developed an approved mRNA (messenger ribonucleic acid) COVID-19 vaccine. This vaccine is designed to mimic (appear like) a surface protein of SARS-CoV-2 to prime the immune system to recognise and clear the virus, providing immunity. As SARS-CoV-2 mutates and new variants emerge, changes to this target antigen have increased viral transmissibility and reduced immunity.
IN002.5.1 is a potential new mRNA COVID-19 booster vaccination which will be compared to a comparator vaccine, Moderna. IN002.5.1 works in a similar way to Moderna but is designed with specific mutations shared across the Delta and Omicron variants. It is hoped that by incorporating these mutations within a vaccine, that IN002.5.1 booster vaccinations can provide enhanced protection against COVID-19.
The purpose of this study is to:
• Evaluate how safe and well tolerated IN002.5.1 is compared to Moderna, in previously vaccinated participants.
• Measure the body’s response to a single dose of IN002.5.1 in previously vaccinated participants.
• Assess how strong the body’s immune response to IN002.5.1 in previously vaccinated participants.
Study Candidates
- Healthy Males and Females
- Previously vaccinated against COVID-19
- Aged 18 – 59 years
- Weight ≥50 kg (males) ≥45 kg (females)
- BMI 18.5 – 35.0 kg/m2
What is Involved?
Study Visits: 7 visits
Reimbursement: $2,200 (less tax)